Cancer Center News

With the majority of Hodgkin lymphoma patients surviving their disease, the focus has turned to minimizing the long-term effects of treatment while maintaining excellent cure rates.

Using the case of a 14-year-old male diagnosed with osteosarcoma, we discuss the diagnosis and treatment of bone cancer with the goal of preserving limbs and functions.

Philanthropy helped CHOP develop the first cell therapy to receive FDA approval and provide lifesaving treatments to 170 children with ALL, like Paulina.

The FDA approval of Kymriah™ has shifted the paradigm for pediatric cancer treatment — and at Children's Hospital of Philadelphia, more cell therapies are on the horizon.

Researchers have found key differences among the most common types of pediatric brain tumors that may lead to more effective therapy.

By identifying common gene variants that raise the risk of an aggressive form of the childhood cancer neuroblastoma, researchers may assist diagnostic efforts.

This is a game changer for the treatment of pediatric patients battling leukemia and a pivotal milestone in this new era of cellular therapies that treat cancer with a patient’s own immune system.

Newly created videos allow families to see the facilities’ interiors and better understand what will happen during an outpatient visit before their scheduled appointment.

Since its inception in October 2016, the workshop has created recommendations for the 50 most common syndromes that predispose children to cancer and produced 16 position papers.

Thanks to a recent initiative at CHOP, patients newly diagnosed with B-cell and T-cell ALL, and lymphoblastic lymphoma, now go home on average 9 days after diagnosis — that's 3 weeks sooner than previous stays.